Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Roivant Sciences's Enterprise Value is €20,130.52 Mil.
Roivant Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-702.48 Mil. Therefore, Roivant Sciences's EV-to-OCF for today is -28.66.
The historical rank and industry rank for Roivant Sciences's EV-to-OCF or its related term are showing as below:
FRA:87S'
s EV-to-OCF Range Over the Past 10 Years
Min: -28.41 Med: -5.31 Max: -1.3
Current: -28.41
During the past 6 years, the highest EV-to-OCF of Roivant Sciences was -1.30. The lowest was -28.41. And the median was -5.31.
FRA:87S's EV-to-OCF is ranked better than 85.93% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs FRA:87S: -28.41
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Roivant Sciences's PE Ratio (TTM) for today is calculated as:
Roivant Sciences's share price for today is €30.11.
Roivant Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.454.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Roivant Sciences EV-to-OCF Related Terms
Roivant Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Roivant Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's EV-to-OCF falls into.
Roivant Sciences's current Enterprise Value is €20,130.52 Mil.
Roivant Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-702.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (FRA:87S) has a EV-to-OCF of -28.66 as of Aug. 09, 2026. According to the industry distribution chart, Roivant Sciences ranks #198 out of 1407 companies in the Biotechnology industry, placing it in the top 14.1%.
Is Roivant Sciences' EV-to-OCF too high?
Roivant Sciences' current EV-to-OCF is -28.66. Based on the distribution chart, Roivant Sciences ranks #198 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' EV-to-OCF compare to RPRX and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #198 out of 1407 companies for EV-to-OCF. This places Roivant Sciences in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Roivant Sciences's current EV-to-OCF is -28.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (FRA:87S) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.51, compared to a current price of €30.11 — trading 1099.6% above its estimated fair value. The current EV-to-OCF is -28.66. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Roivant Sciences (FRA:87S), the current EV-to-OCF is -28.66 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (FRA:87S) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of €30.11 is trading 1099.6% above its estimated GF Value™ of €2.51.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for FRA:87S:
EV-to-OCF: -28.66
GF Value™: €2.51 vs. price of €30.11 (1099.6% above fair value)
No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score
Get the complete analysis for FRA:87S
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:87S has been successfully added to your 
